CEO Christian Leisner identifies a single decision as a game-changing milestone: focusing their T-cell engagers on "clean but challenging" tumour antigens. He vividly recalls the meeting where this choice set a clear, relevant strategic direction that the company still follows years later.
When starting out, CDR Life had no intellectual property, data, or significant money. CEO Christian Leisner credits their success to the founding team's powerful and unwavering belief that they could succeed, which made finding a path forward a manageable challenge.
Typically, the starting dose in a Phase 1 trial is too low to show efficacy. For CDR Life, observing immunological activity and biomarker improvement in their very first patient was a rare and remarkable event that provided the first tangible sign their scientific platform could become a real therapeutic.
With no initial funding, CDR Life leveraged its team's expertise to develop and out-license an ophthalmology program. This non-dilutive deal with Boehringer Ingelheim provided the capital and validation needed to fund its primary mission in oncology and later secure a Series A round.
Beyond a supportive ecosystem, CDR Life's CEO highlights Switzerland's dense concentration of well-trained life science professionals from big pharma, biotech, and top universities as its most critical advantage. This makes it easier to hire and retain the specialized talent essential for a biotech's success.